At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 218 target
Drug / intervention
ABO2011 Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics (PK/PD) and Preliminary Efficacy of ABO2011 Monotherapy or in Combination With Toripalimab in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating ABO2011 Injection and Toripalimab for Solid Tumor, Adult. Currently recruiting, targeting 218 participants across 5 sites.
Signals
Enrolling ahead of pace
Detailed Summary
This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult
CountriesChina
CollaboratorsAbogen Biosciences (Shanghai) Co., Ltd
Timeline
Phase 2Recruiting
20242025202620272028
Enrollment StartSep 2023
First PostedOct 2023
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedOct 18, 2023
Enrollment StartSep 28, 2023
Primary CompletionDec 30, 2026
Study CompletionDec 30, 2027
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 2.7 years agoPrimary completion in 6 months
Interventions
ABO2011 Injectiondrug
Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
Toripalimabdrug
Anti-PD-1 antibody